MARKET

NVUS

NVUS

Novus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3932
+0.0192
+5.13%
Closed 16:00 03/27 EDT
OPEN
0.3800
PREV CLOSE
0.3740
HIGH
0.4068
LOW
0.3750
VOLUME
93.12K
TURNOVER
--
52 WEEK HIGH
4.431
52 WEEK LOW
0.2500
MARKET CAP
6.32M
P/E (TTM)
-0.2793
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NVUS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVUS stock price target is 5.08 with a high estimate of 10.00 and a low estimate of 2.000.

EPS

NVUS News

More
  • Novus Therapeutics EPS misses by $0.06
  • seekingalpha · 03/17 16:34
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
  • Business Wire · 03/17 12:30
  • Novus Therapeutics Q4 EPS $(0.32) Up From $(0.49) YoY
  • Benzinga · 03/17 11:37

Industry

Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About NVUS

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
More

Webull offers kinds of Novus Therapeutics Inc stock information, including NASDAQ:NVUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVUS stock news, and many more online research tools to help you make informed decisions.